Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Jan;5(1):11.
doi: 10.21037/atm.2016.12.64.

Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations

Shinkyo Yoon  1 , Dae Ho Lee  1 , Sang-We Kim  1
Affiliations
Editorial

Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations

Shinkyo Yoon et al. Ann Transl Med. 2017 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Comment on

References

    1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. 10.1056/NEJMoa040938 - DOI - PubMed
    1. Paz-Ares L, Soulières D, Moecks J, et al. Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC. J Cell Mol Med 2014;18:1519-39. 10.1111/jcmm.12278 - DOI - PMC - PubMed
    1. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26. 10.1126/scitranslmed.3002003 - DOI - PMC - PubMed
    1. Kazandjian D, Blumenthal GM, Yuan W, et al. FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer. Clin Cancer Res 2016;22:1307-12. 10.1158/1078-0432.CCR-15-2266 - DOI - PubMed
    1. Park K, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 2016;17:577-89. 10.1016/S1470-2045(16)30033-X - DOI - PubMed